Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claus Garbe

Showing results (231-240 of 501) with videos related to

Pageof 51
Sort By:
Plos One|May 3, 2013
Prognostic factors of melanoma patients with satellite or in-transit metastasis at the time of stage III diagnosisBenjamin Weide, Christine Faller, Petra Büttner, et al.
BMJ Open|December 21, 2016
Study protocol for a prospective, non-controlled, multicentre clinical study to evaluate the diagnostic accuracy of a stepwise two-photon excited melanin fluorescence in pigmented lesions suspicious for melanoma (FLIMMA study)Christine Fink, Maja Hofmann, Agata Jagoda, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 24, 2022
Risk analysis of systemic side effects of tumescent local anaesthesia in the surgical treatment of geriatric and multimorbid patients with skin cancerSaskia Maria Schnabl, Claus Garbe, Helmut Breuninger, et al.
Melanoma Research|July 16, 2008
Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanomaAxel Hauschild, Uwe Trefzer, Claus Garbe, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 25, 2013
Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial)Annette Degen, Michael Weichenthal, Selma Ugurel, et al.
Plos One|March 4, 2014
BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapyDiana Meckbach, Ulrike Keim, Sabina Richter, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 8, 2024
Skin cancer in Europe today and challenges for tomorrowLieve Brochez, Beate Volkmer, Isabelle Hoorens, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 16, 2008
Results of the first phase I/II clinical vaccination trial with direct injection of mRNABenjamin Weide, Jean-Philippe Carralot, Anne Reese, et al.
Plos One|July 5, 2013
Melanoma patients with unknown primary site or nodal recurrence after initial diagnosis have a favourable survival compared to those with synchronous lymph node metastasis and primary tumourBenjamin Weide, Christine Faller, Margrit Elsässer, et al.
European Journal of Cancer (Oxford, England : 1990)|March 22, 2015
443 paediatric cases of malignant melanoma registered with the German Central Malignant Melanoma Registry between 1983 and 2011Ines B Brecht, Claus Garbe, Olaf Gefeller, et al.
Pageof 51

Showing results (231-240 of 501) with videos related to

Sort By:
Pageof 51
Plos One|May 3, 2013
Prognostic factors of melanoma patients with satellite or in-transit metastasis at the time of stage III diagnosisBenjamin Weide, Christine Faller, Petra Büttner, et al.
BMJ Open|December 21, 2016
Study protocol for a prospective, non-controlled, multicentre clinical study to evaluate the diagnostic accuracy of a stepwise two-photon excited melanin fluorescence in pigmented lesions suspicious for melanoma (FLIMMA study)Christine Fink, Maja Hofmann, Agata Jagoda, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 24, 2022
Risk analysis of systemic side effects of tumescent local anaesthesia in the surgical treatment of geriatric and multimorbid patients with skin cancerSaskia Maria Schnabl, Claus Garbe, Helmut Breuninger, et al.
Melanoma Research|July 16, 2008
Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanomaAxel Hauschild, Uwe Trefzer, Claus Garbe, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 25, 2013
Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial)Annette Degen, Michael Weichenthal, Selma Ugurel, et al.
Plos One|March 4, 2014
BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapyDiana Meckbach, Ulrike Keim, Sabina Richter, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 8, 2024
Skin cancer in Europe today and challenges for tomorrowLieve Brochez, Beate Volkmer, Isabelle Hoorens, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 16, 2008
Results of the first phase I/II clinical vaccination trial with direct injection of mRNABenjamin Weide, Jean-Philippe Carralot, Anne Reese, et al.
Plos One|July 5, 2013
Melanoma patients with unknown primary site or nodal recurrence after initial diagnosis have a favourable survival compared to those with synchronous lymph node metastasis and primary tumourBenjamin Weide, Christine Faller, Margrit Elsässer, et al.
European Journal of Cancer (Oxford, England : 1990)|March 22, 2015
443 paediatric cases of malignant melanoma registered with the German Central Malignant Melanoma Registry between 1983 and 2011Ines B Brecht, Claus Garbe, Olaf Gefeller, et al.
Pageof 51